Pro Medicus (PMCUF) Stock Price, News & Analysis

Company Overview

Pro Medicus Limited is an Australia‐based healthcare technology company specializing in advanced medical imaging IT solutions. Its core offerings include radiology information systems (RIS), picture archiving and communication systems (PACS), and enterprise imaging platforms designed to streamline diagnostic workflows and enhance image management for healthcare providers.

The company’s flagship product suite, Visage 7, delivers high-performance visualization and reporting capabilities, enabling radiologists to access and manipulate large datasets with minimal latency. Pro Medicus also provides complementary modules for artificial intelligence integration, data analytics, and teleradiology, supporting both on-premises and cloud-based deployment models.

Founded in 1983 and headquartered in Melbourne, Pro Medicus has expanded its footprint to serve hospitals, imaging centers, and academic medical institutions across Australia, Europe, and North America. Key installations include major health systems and specialist clinics that rely on Pro Medicus solutions to manage high-volume imaging workloads and to collaborate seamlessly across multidisciplinary care teams.

Over its history, Pro Medicus has built a reputation for rapid image delivery and scalable architecture, earning partnerships with leading medical research centers and device vendors. The company is led by an experienced executive team with deep expertise in medical imaging, software engineering, and healthcare operations, driving its mission to improve patient outcomes through innovative information technology.

Key Stats

• Today's Range: $111.52 to $118.13
• 50-Day Range: $86.49 to $121.79
• 52-Week Range: $74.52 to $218.25
• Volume: 73 shs
• Average Volume: 748 shs
• Market Capitalization: N/A
• P/E Ratio: 7,875.00
• Dividend Yield: 0.02%
• Price Target: $155.00
• Consensus Rating: Buy

Pro Medicus Stock Analysis - MarketRank™

Pro Medicus scored higher than 32% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Pro Medicus has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and no sell ratings.

Upside Potential

Pro Medicus has a consensus price target of $155.00, representing about 31.2% upside from its current price of $118.13.

Amount of Analyst Coverage

Pro Medicus has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Pro Medicus is 7,875.00, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 38.91.

Price to Earnings Ratio vs. Sector

The P/E ratio of Pro Medicus is 7,875.00, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 24.50.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Pro Medicus has a short interest ratio ("days to cover") of 230.75, which indicates bearish sentiment.

Change versus previous month

Short interest in Pro Medicus has recently decreased by 0.05%, indicating that investor sentiment is improving.

Dividend

• Score: 0.8 / 5
• Dividend Strength: Weak

Dividend Yield

Pro Medicus pays a meaningful dividend of 1.63%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Pro Medicus does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Pro Medicus is 133.33%. Payout ratios above 75% are not desirable because they may not be sustainable.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Pro Medicus insiders have not sold or bought any company stock.

Percentage Held by Institutions

10.84% of the stock of Pro Medicus is held by institutions.

Company Calendar

• Today: 6/19/2026
• Next Earnings (Estimated): 8/19/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Health Information Services
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:PMCUF
• CIK: 2013003
• Web: www.promed.com.au
• Phone: 61 3 9429 8800
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Pro Medicus: $155.00
• High Price Target: $155.00
• Low Price Target: $155.00
• Potential Upside/Downside: +31.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: 7,875.00
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A